Introduction
 Two-drug regimens (2DRs) are being evaluated against standard 3-drug regimens for their potential to reduce cumulative drug exposure and drug-drug interactions during lifelong antiretroviral therapy (ART) in people living with HIV  We evaluated the 2DR of DTG + 3TC in 2 identical global, double-blind, multicenter, phase III studies GEMINI-1 and -2 (ClinicalTrials.gov: NCT02831673/NCT02831764)  Primary endpoint results were previously presented: DTG + 3TC was non-inferior to DTG + TDF/FTC at Week 48. No participants who met protocol-defined virologic withdrawal criteria had treatment-emergent INSTI or NRTI resistance mutations 1
Methods
 Study design: Phase III, randomized (1:1), double-blind, parallel-group  Participants received either DTG + 3TC (N=716) or DTG + TDF/FTC (N=717)
 Stratification: By Screening plasma HIV-1 RNA (≤100,000 vs >100,000 c/mL) and CD4+ cell count (≤200 vs >200 cells/mm 3 )  Key eligibility criteria: ≥18 years of age; ART naive (≤10 days of prior ART); no evidence of pre-existing major resistance-associated mutations; no hepatitis B virus infection; HIV-1 RNA 1000 to 500,000 c/mL  Primary endpoint: Proportion with plasma HIV-1 RNA <50 c/mL at Week 48 using snapshot algorithm; −10% non-inferiority margin  Subgroup analyses: Snapshot outcomes and adverse event (AE) frequencies by demographics and Baseline HIV-1 RNA and CD4+ cell count  Statistical analysis: For the primary endpoint, estimates and confidence intervals (CIs) were based on a stratified analysis using Cochran-Mantel-Haenszel weights. The subgroup analyses were unadjusted 
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Efficacy
 Subgroup analyses of efficacy based on baseline disease and demographic characteristics were generally consistent with overall study results ( Figure)  In the CD4+ count ≤200 cells/mm 3 subgroup, most reasons for snapshot non-response were not related to efficacy or treatment (eg, non-treatmentrelated AEs;  In GEMINI-1 and -2, DTG + 3TC demonstrated non-inferior efficacy to DTG + TDF/FTC in treatment-naive adults with Screening HIV-1 RNA ≤500,000 c/mL at Week 48. Both regimens were well tolerated  Subgroup analyses of efficacy and AEs performed based on baseline disease and demographic characteristics were generally consistent with overall study results  Response rates in participants with Baseline HIV-1 RNA >100,000 c/mL were high and similar between arms  Response rates in participants with Baseline CD4+ ≤200 cells/mm 3 were lower in the DTG + 3TC arm compared with DTG + TDF/FTC; however, snapshot failures were predominantly for reasons unrelated to efficacy or treatment  DTG + 3TC is a robust option for treatment of HIV-infected patients across a spectrum of disease characteristics and patient populations  The studies are ongoing to explore long-term durability and safety
